2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

Abstract Number: 2412

Valdiation of a Diagnosis of Gout in the Epiccare Electronic Medical Records
Abstract Number: 542

Validation of a Reference Imaging Module for Calibration of Readers Scoring with the Modified Stoke Ankylosing Spondylitis Spine Score
Abstract Number: 1314

Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients
Abstract Number: 1171

Validation of BASDAI and BASFI in Children with Spondyloarthritis
Abstract Number: 2551

Validation of EULAR Primary Sjögren’s Syndrome Disease Activity and Patient Indexes
Abstract Number: 2118

Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria
Abstract Number: 288

Validation of Promis Modules for Use in Childhood-Onset Lupus
Abstract Number: 80

Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Patient Reported Outcomes Analyzed From 3 Phase III Golimumab Trials
Abstract Number: 1345

Validation of the Health Assessment Questionnaire for Spondyloarthritis in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 1701

Validation of the New ASAS Criteria for Classification of Early Spondyloarthritis in the Esperanza Cohort
Abstract Number: 1363

Validation of the Self-Administered Comorbidity Questionnaire in Patients with Ankylosing Spondylitis
Abstract Number: 942

Validity and Reliability of the Lupus Damage Index Questionnaire (LDIQ): A Prospective Study
Abstract Number: 941

Validity and Reliability of the Systemic Lupus Activity Questionnaire (SLAQ): A Prospective Study
Abstract Number: 1378

Validity of Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients with Early Spondyloarthritis
Abstract Number: 2193

Validity of Low Titers of SSA/B Antibodies in Predicting A Key Feature of Sjögren’s Syndrome
Abstract Number: 1584

Validity of the Nurses Health Study II Physical Activity Questionnaire (NHSPAQ) in Estimating Physical Activity in Adults with Rheumatoid Arthritis (RA)
Abstract Number: 1374

Value of C-Reactive Protein Level At Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors
Abstract Number: 1849

Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Abstract Number: 82

Variability of the SF-6D Determinants Over Time in Early Arthritis:Results From the Espoir Cohort
Abstract Number: 287

Variation in Healthcare Utilization by Region and Number of Rheumatologists Per State Among Pediatric Medicaid Patients with Lupus Nephritis Prior to End-Stage Renal Disease in the United States, 2000-2004
Abstract Number: 1896

Variation in US Pediatric Rheumatology Fellowship Training
Abstract Number: 2271

Variation of Interferon-Alpha Production in Healthy Individuals and Association with Autoimmune Susceptibility Genes
Abstract Number: 1264

Vascular Age in Rheumatoid Arthritis Patients
Abstract Number: 1255

Vascular Calcification On Hand and Feet X-Rays, VFA Imaging of the Spine, and Cardiovascular Disease in Rheumatoid Arthritis
Abstract Number: 1412

Vascular Cell Adhesion Molecule (VCAM-1) and Angiostatin in Systemic Lupus Erythematosus
Abstract Number: 701

Vascular Differences Associated to Genetic Polymorphisms of Endothelial Nitric Oxide Synthase in Mexican Patients with Systemic Sclerosis. A Preliminary Report
Abstract Number: 703

Vascular Ischemic Events in Systemic Sclerosis – A Cross-Sectional Comparision with Population-based Controls
Abstract Number: 1423

Vascular Thrombosis and Pregnancy Morbidity in Patients with Systemic Lupus Erythematosus with Positive Antiphospholipid Profile and Thrombocytopenia
Abstract Number: 1686

Vertebral Fracture Assessment-Detected Abdominal Aortic Calcification Enhances Cardiovascular Disease Risk Stratification of Rheumatoid Arthritis Patients
Abstract Number: 13

Visfatin/Nampt in Osteoarthritis: Sites of Production in Human Joints and Role of Its Enzymatic Activity
Abstract Number: 2356

Visual Manifestations in Giant Cell Arteritis : Trend Over Five Decades
Abstract Number: 1019

Visualization of Cartilage in High-Resolution Magnetic Resonance Imaging Is a New Imaging Biomarker for the Quantification of Joint Damage in Rheumatoid Arthritis
Abstract Number: 2245

Vitamin D Deficiency Is Associated with, but Does Not Predict, Change in hsCRP in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1390

Vitamin D Deficiency Is Not Associated with Nor Does It Predict Progression of Coronary Artery Calcium or Carotid Intima-Media Thickness in Systemic Lupus Erythematosus
Abstract Number: 1179

Vitamin D Receptor Polymorphisms Are Associated with Clinical Outcomes and IgM Responses to Common Pathogens but Not Baseline Disease Activity in Early Inflammatory Arthritis
Abstract Number: 1251

Vulnerability Features Are Common in Coronary Plaques of Asymptomatic Patients with Rheumatoid Arthritis Compared to Controls: Associations with Lipid and Oxidative Stress Biomarkers

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].